FDA approves Takeda's orexin drug for narcolepsy type 1

Takeda has received FDA approval for its orexin agonist intended to treat narcolepsy type 1.

The decision ends a closely watched commercial race to bring an orexin-based therapy to market.

With approval secured, the drug can now be launched, offering a new option for patients living with the disorder.